Therapeutic flag Cosmetic cross-reference

Piracetam

CAS 7491-74-9

Piracetam (CAS 7491-74-9) is a Phase 3 pharmaceutical compound with 3 bioactivity targets and 130 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
3
SOURCE DrugCentral
Adverse signals
130
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Piracetam
CAS Number
7491-74-9
UNII
ZH516LNZ10
InChIKey
GMZVRMREEHBGGF-UHFFFAOYSA-N
ChEMBL ID
CHEMBL36715
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural producttherapeutic flag
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3
Late-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL36715 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 3 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 29999.227027027024 nM 74 -
- Potency 22686.107999999997 nM 18 -
- IC50 19976.309999999998 nM 1 -
SOURCE DrugCentral 13 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Central nervous system injury 9 60.84 10081266
Parkinsonism 19 51.459 10034010
Splenic injury 8 47.667 10041649
Hyperchloraemia 10 46.406 10020597
Intestinal pseudo-obstruction 11 44.406 10022698
Hypochromasia 8 40.257 10050789
Neuroleptic malignant syndrome 18 39.994 10029282
Anisocytosis 8 35.221 10002536
Petechiae 15 34.113 10034754
Tremor 31 29.007 10044565
Macrocytosis 8 27.698 10025382
Hyperaemia 8 27.644 10020565
Aggression 18 27.564 10001488

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 4 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
GluA1
GRIA1
 Positive - -
GluA2
GRIA2
 Positive - -
GluA3
GRIA3
 Positive - -
GluA4
GRIA4
 Positive - -
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Piracetam used for in pharmaceutical contexts?

Piracetam (CAS 7491-74-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Piracetam?

Piracetam has 130 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Central nervous system injury, Parkinsonism, Splenic injury, Hyperchloraemia, Intestinal pseudo-obstruction. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Piracetam also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Piracetam with EU status "prohibited".

What clinical phase is Piracetam in?

Piracetam is rendered with ChEMBL max phase 3.